Baidu
map

Antimicrob Agents Chemother:患有急性中耳炎少年儿童中,克拉维酸减少浓度疗效研究

2017-04-30 AlexYang MedSci原创

阿莫西林/克拉维酸(A/C)是目前治疗儿童急性中耳炎(AOM)最有效的口服抗菌药物,但是标准剂量 90/6.4 mg/kg/day通常会引起腹泻。最近,有研究就是否能改变A/C用药规则,即更低浓度的克拉维酸可以导致更少的腹泻进行了研究,同时保持阿莫西林和克拉维酸血药浓度足够根除中耳病原物从而获得临床成功。研究人员设计了一个在年龄为6个月到23个月患有AOM的群体中的开放式研究。在研究第一阶段,研究

阿莫西林/克拉维酸(A/C)是目前治疗儿童急性中耳炎(AOM)最有效的口服抗菌药物,但是标准剂量 90/6.4 mg/kg/day通常会引起腹泻。最近,有研究就是否能改变A/C用药规则,即更低浓度的克拉维酸可以导致更少的腹泻进行了研究,同时保持阿莫西林和克拉维酸血药浓度足够根除中耳病原物从而获得临床成功。

研究人员设计了一个在年龄为6个月到23个月患有AOM的群体中的开放式研究。在研究第一阶段,研究人员对40名儿童进行了减少的克拉维素A/C用药规则,即提供为期10天的80/3.2 mg/kg/day用药量。在第二阶段,研究人员对72名儿童进行了同样的用药规则,剂量为80/2.85 mg/kg/day。之后,研究人员对比了这些儿童协议定义腹泻(PDD)、尿布皮炎比例和AOM临床反应,以及他们之前报道的接受标准A/C规则比例,研究人员同样获得多个时间点的了阿莫西林和克拉维酸的血药浓度。研究发现,阶段一和标准规则下儿童没有显著差异。PDD比例在阶段二和标准规则中分别为17%和26%(P=0.01)。相关的尿布皮炎比例分别为22%和34&(P=0.04),AOM治疗失败比例分别为12%和16%(P=0.44)。症状响应在不同的用药规则下没有显著的差异,都表现出了抑制β-内酰胺酶活性足够的克拉维酸水平。在AOM少年儿童中,比目前标准规则用药更低的克拉维酸剂量也许与更少的负作用并且没有减少临床效果有关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2018-04-03 grace5700
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-10-23 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-11-12 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1779483, encodeId=9b051e7948353, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Tue Apr 03 17:15:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779545, encodeId=92511e79545a2, content=<a href='/topic/show?id=0473209562' target=_blank style='color:#2F92EE;'>#agents#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2095, encryptionId=0473209562, topicName=agents)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Oct 23 10:15:00 CST 2017, time=2017-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084210, encodeId=964e208421084, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Nov 12 08:15:00 CST 2017, time=2017-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2052527, encodeId=9fc6205252eaa, content=<a href='/topic/show?id=a03f288e664' target=_blank style='color:#2F92EE;'>#克拉维酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28876, encryptionId=a03f288e664, topicName=克拉维酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Thu Oct 05 19:15:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857442, encodeId=4d1d185e44222, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 20 22:15:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344485, encodeId=e3c4134448590, content=<a href='/topic/show?id=a01b2239e0b' target=_blank style='color:#2F92EE;'>#中耳炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22397, encryptionId=a01b2239e0b, topicName=中耳炎)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544442, encodeId=8692154444209, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue May 02 01:15:00 CST 2017, time=2017-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192182, encodeId=6bc91921825c, content=有意义的临床研究。, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Sun Apr 30 13:06:06 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 cqykthl

    有意义的临床研究。

    0

相关资讯

NEJM:急性中耳炎患儿的抗菌药时间是否应该缩短?

限制抗微生物治疗的持续时间是降低急性中耳炎儿童的抗微生物耐药性的一项潜在策略。近期,一项发表在NEJM杂志上的文章研究了减少给予抗生素时间对急性中耳炎患儿是否有利。研究者们予以520名6个月至23个月龄的急性中耳炎儿童阿莫西林 - 克拉维酸治疗,分为10天的标准持续时间治疗组以及5天治疗持续时间后为5天的安慰剂治疗组。研究者们监测了临床反应率(以系统的方式,基于体征和症状反应)、复发和鼻咽定植菌。

2015儿童急性中耳炎诊疗—临床实践指南发布

2014年末,中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会提出了制定《儿童急性中耳炎诊疗—— 临床实践指南》(以下简称《指南》)的设想,由两位儿童耳鼻咽喉科专家起草初稿,并于2015年初在昆明由6位儿童耳鼻咽喉科资深专家对《指南》初稿进行了充分讨论;同年7月,由儿童耳鼻咽喉科与呼吸科共计16位专家在成都进行了第2稿的讨论,会议期间,与会专家提出了宝贵建议,在此基础上又进一步修改;经过充分的讨论、

Salvat和Arbor宣布推出OTOVEL(R)滴耳液

Laboratorios SALVAT S.A.(简称“Salvat”)和Arbor Pharmaceuticals, LLC (简称“Arbor”)共同宣布推出OTOVEL®(环丙沙星0.3%和氟氢松0.025%)滴耳液。这是首款且唯一一款抗生素和类固醇组合滴耳液,采用单一、无菌、无防腐剂的单位剂量包装。OTOVEL 由 Salvat 所有,Arbor将是该产品在美国的独家分销商。

Baidu
map
Baidu
map
Baidu
map